Amgen and Sanofi settle Repatha IP fight — legal overhang removed
Key Questions
What was the outcome of the Amgen-Sanofi Repatha IP dispute?
Amgen and Sanofi settled their intellectual property fight over Repatha in mid-March 2026, clearing Supreme Court overhang. This removes legal uncertainty ahead of April earnings.
What are the key results from the Vesalius-CV Phase 3 trial for Repatha?
The trial showed a 31% reduction in MACE for high-risk diabetes patients, published in JAMA/ACC on March 28. Annual sales are projected at $1.5 billion.
How have Canadian provinces expanded Repatha coverage?
Ontario and Quebec expanded public coverage for Repatha to 52 weeks and 24 months post-ACS patients, respectively. This boosts access and supports Amgen's 2030 cardiovascular goals.
What risks does Repatha face in Europe?
EU pricing risks persist despite positive trial data and coverage expansions. Settlement terms will be detailed pre-April 30 earnings.
How does Repatha fit into Amgen's broader cardiovascular strategy?
Repatha supports Amgen's ambition to halve US cardiovascular events by 2030. Positive data and expanded access enhance its role amid safe dividend stock status.
Mid-March 2026 settlement clears SCOTUS. Ph3 Vesalius-CV 31% MACE cut diabetes high-risk (JAMA/ACC Mar28, $1.5B ann proj). Ontario/Quebec public coverage expansions (52w/24mo post-ACS) boost access. Supports 2030 CV goal; EU pricing risks; terms pre-Apr30 earnings.